GlobalData on MSN
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.
Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals promising five-year results.
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results